We performed the meta‐analysis on EGFR positive tumor NSCLC from 35 studies and noted that EGFR+ in both tumor tissue and plasma at baseline is the worse prognostic factor for PFS and OS. This evidence concerns the gene EGFR and non-small cell lung carcinoma.